• COVID-19 Vaccines Effective Against Delta Variant?

    From _@21:1/5 to All on Sun Sep 12 12:46:52 2021
    (re-post to insure clarification regarding who has
    & has not been approved for a 3rd booster vac-
    cination in the U.S.)

    Disclaimer / Clarifier 1: Scientists say these findings
    need further monitoring and evaluation.

    Disclaimer / Clarifier 2: Reported elsewhere, a 3rd
    booster vaccination will be needed 6 to 8 months
    after one is fully vaccinated, but that has only been
    approved in the U.S. for "7 million severely immuno-
    compromised people" per following 2 posts: https://groups.google.com/g/misc.health.diabetes/c/IdVInZEhl8k/m/FuBTZ8_aAQAJ https://groups.google.com/g/misc.health.diabetes/c/IdVInZEhl8k/m/7C9e3_09AgAJ

    It has only been approved for the "7 million severely
    immunocompromised people" in the U.S. detailed
    above, but it has not yet been approved for anyone
    else in the U.S. (it has been approved at the 6 month
    point in Israel).

    - - - - - - - - -

    - - -
    By Regenstrief Institute September 12, 2021

    How Pfizer / Moderna / Johnson & Johnson
    COVID-19 Vaccines Compare https://scitechdaily.com/covid-19-vaccines-effective-against-delta-variant-how-pfizer-moderna-and-jj-compare/
    - - -

    Data from a national study shows that COVID-19
    vaccines are effective at preventing hospitalizations
    & emergency department visits caused by the Delta
    variant.

    COVID-19 vaccines are effective at preventing hos-
    pitalizations & emergency department visits caused
    by the Delta variant, according to data from a national
    study.

    That data also indicate that Moderna’s vaccine is sig-
    nificantly more effective against Delta than Pfizer &
    Johnson & Johnson. “These real-world data show that
    vaccines remain highly effective at reducing COVID-19
    related hospitalizations & emergency department visits,
    even in the presence of the new COVID-19 variant.” ...

    “We strongly recommend vaccinations for all who are
    eligible to reduce serious illness and ease the burden
    on our healthcare system.”

    The Centers for Disease Control & Prevention (CDC)’s
    VISION Network analyzed more than 32,000 medical
    encounters from 9 states during June, July, & August
    2021, when the Delta variant became the predominant
    strain.

    The results showed that unvaccinated individuals with
    COVID-19 are 5-7 times more likely to need emergency
    department care or hospitalization, similar to the overall
    effectiveness prior to the variant.

    The study in Morbidity and Mortality Weekly Report is
    also the first analysis from the VISION Network to show
    a marked difference between the effectiveness of the
    mRNA vaccines (Moderna & Pfizer). In the study’s time
    period:

    o Moderna was 95% effective at preventing hospitaliza-
    tions among adults ages 18 and older.

    o Pfizer was 80% effective at preventing hospitalizations
    among adults ages 18 and older.

    o Johnson & Johnson was 60% effective at preventing
    hospitalizations among adults ages 18 and older.

    The study also found that vaccine effectiveness is lower
    for people 75 years & older, which has not been shown
    in previous research. This could be due to a range of
    factors, including the increased time since vaccination.

    When it came to preventing emergency department &
    urgent care visits, analysis showed that:

    o Moderna was 92% effective.

    o Pfizer was 77% effective.

    o Johnson & Johnson was 65% effective.

    “Despite the differences in effectiveness, vaccines con-
    tinue to offer much more protection than not getting one
    at all.” ... “While breakthrough cases do happen, data
    shows the symptoms are less severe. The vast majority
    of COVID hospitalizations & deaths continue to be among
    unvaccinated individuals. COVID-19 vaccines are power-
    ful tools for combating the pandemic.”

    The VISION network, funded by the CDC, includes 7 org-
    anizations that contribute & analyze data from U.S. health-
    care systems to learn more about the COVID-19 vaccine
    effectiveness. In addition to Regenstrief Institute, other
    members are

    o Columbia University Irving Medical Center,
    o HealthPartners,
    o Intermountain Healthcare, Kaiser Permanente Northern
    California,
    o Kaiser Permanente Northwest,
    &
    o University of Colorado.

    ...

    - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
    Diabetes Bubble / Diabetes Bubble Burst https://prohuman.net/diabetesbubblediabetesbubbleburst.htm

    C.ure I.nsulinitis A.ssociation https://prohuman.net/cureinsulinitisassociation.htm

    Glucose Anomalies Research regarding
    Potential Cures / Improvements in Treatments https://prohuman.net/glucoseanomaliesresearch.htm
    - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

    --- SoupGate-Win32 v1.05
    * Origin: fsxNet Usenet Gateway (21:1/5)
  • From _@21:1/5 to All on Sun Sep 12 12:40:03 2021
    Disclaimer / Clarifier 1: Scientists say these findings
    need further monitoring and evaluation.

    Disclaimer / Clarifier 2: Reported elsewhere, a 3rd
    booster vaccination will be needed 6 to 8 months
    after one is fully vaccinated, but that has only been
    approved for "7 million severely immunocompro-
    mised people" per following 2 posts: https://groups.google.com/g/misc.health.diabetes/c/IdVInZEhl8k/m/FuBTZ8_aAQAJ https://groups.google.com/g/misc.health.diabetes/c/IdVInZEhl8k/m/7C9e3_09AgAJ

    It has not yet been approved in the U.S. (it has been
    approved at the 6 month point in Israel).

    - - - - - - - - -

    - - -
    By Regenstrief Institute September 12, 2021

    How Pfizer / Moderna / Johnson & Johnson
    COVID-19 Vaccines Compare https://scitechdaily.com/covid-19-vaccines-effective-against-delta-variant-how-pfizer-moderna-and-jj-compare/
    - - -

    Data from a national study shows that COVID-19
    vaccines are effective at preventing hospitalizations
    & emergency department visits caused by the Delta
    variant.

    COVID-19 vaccines are effective at preventing hos-
    pitalizations & emergency department visits caused
    by the Delta variant, according to data from a national
    study.

    That data also indicate that Moderna’s vaccine is sig-
    nificantly more effective against Delta than Pfizer &
    Johnson & Johnson. “These real-world data show that
    vaccines remain highly effective at reducing COVID-19
    related hospitalizations & emergency department visits,
    even in the presence of the new COVID-19 variant.” ...

    “We strongly recommend vaccinations for all who are
    eligible to reduce serious illness and ease the burden
    on our healthcare system.”

    The Centers for Disease Control & Prevention (CDC)’s
    VISION Network analyzed more than 32,000 medical
    encounters from 9 states during June, July, & August
    2021, when the Delta variant became the predominant
    strain.

    The results showed that unvaccinated individuals with
    COVID-19 are 5-7 times more likely to need emergency
    department care or hospitalization, similar to the overall
    effectiveness prior to the variant.

    The study in Morbidity and Mortality Weekly Report is
    also the first analysis from the VISION Network to show
    a marked difference between the effectiveness of the
    mRNA vaccines (Moderna & Pfizer). In the study’s time
    period:

    o Moderna was 95% effective at preventing hospitaliza-
    tions among adults ages 18 and older.

    o Pfizer was 80% effective at preventing hospitalizations
    among adults ages 18 and older.

    o Johnson & Johnson was 60% effective at preventing
    hospitalizations among adults ages 18 and older.

    The study also found that vaccine effectiveness is lower
    for people 75 years & older, which has not been shown
    in previous research. This could be due to a range of
    factors, including the increased time since vaccination.

    When it came to preventing emergency department &
    urgent care visits, analysis showed that:

    o Moderna was 92% effective.

    o Pfizer was 77% effective.

    o Johnson & Johnson was 65% effective.

    “Despite the differences in effectiveness, vaccines con-
    tinue to offer much more protection than not getting one
    at all.” ... “While breakthrough cases do happen, data
    shows the symptoms are less severe. The vast majority
    of COVID hospitalizations & deaths continue to be among
    unvaccinated individuals. COVID-19 vaccines are power-
    ful tools for combating the pandemic.”

    The VISION network, funded by the CDC, includes 7 org-
    anizations that contribute & analyze data from U.S. health-
    care systems to learn more about the COVID-19 vaccine
    effectiveness. In addition to Regenstrief Institute, other
    members are

    o Columbia University Irving Medical Center,
    o HealthPartners,
    o Intermountain Healthcare, Kaiser Permanente Northern
    California,
    o Kaiser Permanente Northwest,
    &
    o University of Colorado.

    ...

    - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
    Diabetes Bubble / Diabetes Bubble Burst https://prohuman.net/diabetesbubblediabetesbubbleburst.htm

    C.ure I.nsulinitis A.ssociation https://prohuman.net/cureinsulinitisassociation.htm

    Glucose Anomalies Research regarding
    Potential Cures / Improvements in Treatments https://prohuman.net/glucoseanomaliesresearch.htm
    - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

    --- SoupGate-Win32 v1.05
    * Origin: fsxNet Usenet Gateway (21:1/5)